This inventor holds 6 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 3 EPO patents. Top assignees: Sankyo Company, Limited, Daiichi Sankyo Company, Limited, Ono Pharmaceutical Co., Ltd.. Active years: 2006-2016.
Company Filing History:
3 out of 613 
1 out of 461 
1 out of 575 
Years Active: 2006-2016
Title: Tohru Funahashi: Innovator in Pharmaceutical Advancements
Introduction
Tohru Funahashi is a notable inventor based in Suita, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the enhancement of adiponectin production and the development of anti-tumor agents. With a total of 6 patents to his name, Funahashi's work has the potential to impact the treatment of various health conditions.
Latest Patents
Among his latest patents, Funahashi has developed a pharmaceutical composition aimed at enhancing adiponectin production. This invention is particularly relevant for the treatment or prevention of hypoadiponectinemia, utilizing an HMG-CoA reductase inhibitor as the active ingredient. Additionally, he has created a new anti-tumor agent that incorporates adiponectin as an active ingredient. This agent is designed to inhibit carcinogenesis in the liver and offers a prophylactic or therapeutic method against tumors. The administration of this anti-tumor agent can be conducted either orally or through parenteral means, with specific dosage recommendations for intravenous injection.
Career Highlights
Throughout his career, Tohru Funahashi has worked with prominent companies in the pharmaceutical industry, including Sankyo Company, Limited and Ono Pharmaceutical Co., Ltd. His experience in these organizations has contributed to his expertise and innovative capabilities in the field.
Collaborations
Funahashi has collaborated with notable colleagues such as Yuji Matsuzawa and Shinji Tamura. These partnerships have likely fostered a creative environment that encourages the development of groundbreaking pharmaceutical solutions.
Conclusion
Tohru Funahashi's contributions to the pharmaceutical industry, particularly in the areas of adiponectin enhancement and anti-tumor agents, showcase his innovative spirit and dedication to improving health outcomes. His work continues to pave the way for advancements in medical treatments.